Frontiers in cancer immunotherapy - A symposium report Editorial


Authors: Cable, J.; Greenbaum, B.; Pe'er, D.; Bollard, C. M.; Bruni, S.; Griffin, M. E.; Allison, J. P.; Wu, C. J.; Subudhi, S. K.; Mardis, E. R.; Brentjens, R.; Sosman, J. A.; Cemerski, S.; Zavitsanou, A. M.; Proia, T.; Egeblad, M.; Nolan, G.; Goswami, S.; Spranger, S.; Mackall, C. L.
Title: Frontiers in cancer immunotherapy - A symposium report
Abstract: Cancer immunotherapy has dramatically changed the approach to cancer treatment. The aim of targeting the immune system to recognize and destroy cancer cells has afforded many patients the prospect of achieving deep, long-term remission and potential cures. However, many challenges remain for achieving the goal of effective immunotherapy for all cancer patients. Checkpoint inhibitors have been able to achieve long-term responses in a minority of patients, yet improving response rates with combination therapies increases the possibility of toxicity. Chimeric antigen receptor T cells have demonstrated high response rates in hematological cancers, although most patients experience relapse. In addition, some cancers are notoriously immunologically "cold" and typically are not effective targets for immunotherapy. Overcoming these obstacles will require new strategies to improve upon the efficacy of current agents, identify biomarkers to select appropriate therapies, and discover new modalities to expand the accessibility of immunotherapy to additional tumor types and patient populations. © 2020 New York Academy of Sciences.
Keywords: immunotherapy; cancer vaccine; tumor microenvironment; immune evasion; t cell therapy; immuno-oncology; checkpoint inhibitors; neoantigen; immunogenomics; car t
Journal Title: Annals of the New York Academy of Sciences
Volume: 1489
Issue: 1
ISSN: 0077-8923
Publisher: John Wiley & Sons  
Date Published: 2021-04-01
Start Page: 30
End Page: 47
Language: English
DOI: 10.1111/nyas.14526
PUBMED: 33184911
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 3 May 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Renier J Brentjens
    286 Brentjens
  2. Dana Pe'er
    110 Pe'er